JP2005523263A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523263A5
JP2005523263A5 JP2003563565A JP2003563565A JP2005523263A5 JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5 JP 2003563565 A JP2003563565 A JP 2003563565A JP 2003563565 A JP2003563565 A JP 2003563565A JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
fibrosis
composition according
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003563565A
Other languages
Japanese (ja)
Other versions
JP2005523263A (en
Filing date
Publication date
Priority claimed from GBGB0202254.9A external-priority patent/GB0202254D0/en
Application filed filed Critical
Publication of JP2005523263A publication Critical patent/JP2005523263A/en
Publication of JP2005523263A5 publication Critical patent/JP2005523263A5/ja
Pending legal-status Critical Current

Links

Claims (11)

ｃＧＭＰ ＰＤＥ５阻害剤を含む、瘢痕化を減少させるため及び／又は繊維症を治療するための医薬組成物。 A pharmaceutical composition for reducing scarring and / or treating fibrosis, comprising a cGMP PDE5 inhibitor . 瘢痕化及び／又は繊維症に関連した疾患が：
肺繊維症；アテローム性動脈硬化症；心血管疾患；感染、障害、外科処置若しくは熱傷の後の皮膚及び角膜瘢痕化及び／又は繊維症；強皮症及び他の結合組織障害；心臓の繊維症；慢性閉塞性肺疾患；筋繊維症；腎繊維症；慢性皮膚潰瘍及び脂質皮膚硬化症；（あらゆる原因による）肺繊維症；外科処置後及び特発性（idiophatic）の癒着；皮膚の炎症性状態（苔癬状態及びそれに関連する状態も含まれる）；老化及び全ての老化関連変性障害（皮膚の老化も含まれる）；あらゆる病因（ウイルス性及び非ウイルス性肝炎が含まれる）による肝臓繊維症；肝硬変；慢性膵炎；慢性甲状腺炎；（あらゆる原因による）石灰沈着症；その病原が結合マトリックスの沈着／リモデリングに関連する状態（ガンも含まれる）
から選択される、請求項１記載の医薬組成物。 Diseases associated with scarring and / or fibrosis include:
Pulmonary fibrosis; atherosclerosis; cardiovascular disease; skin and corneal scarring and / or fibrosis after infection, injury, surgery or burns; scleroderma and other connective tissue disorders; cardiac fibrosis Chronic obstructive pulmonary disease; myofibrosis; renal fibrosis; chronic skin ulcers and lipid sclerosis; pulmonary fibrosis (due to any cause); post-surgical and idiophatic adhesions; (Including lichen status and related conditions); aging and all aging-related degenerative disorders (including skin aging); liver fibrosis of any etiology (including viral and non-viral hepatitis); Cirrhosis; chronic pancreatitis; chronic thyroiditis; calcification (by any cause); conditions whose pathogenesis is associated with deposition / remodeling of the binding matrix (including cancer)
The pharmaceutical composition according to claim 1, which is selected from: 前記阻害剤が経口投与又は局所投与される、請求項１又は２に記載の医薬組成物。 The pharmaceutical composition according to claim 1 or 2, wherein the inhibitor is administered orally or topically. 前記阻害剤が１００ｎＭ未満のＩＣ５０を有する、請求項１〜３のいずれか１項に記載の医薬組成物。 4. The pharmaceutical composition according to any one of claims 1 to 3 , wherein the inhibitor has an IC50 of less than 100 nM. 前記阻害剤が１０００を超える選択性比を有する、請求項４記載の医薬組成物。 The pharmaceutical composition according to claim 4 , wherein the inhibitor has a selectivity ratio of greater than 1000. 前記阻害剤がシルデナフィルである、請求項１〜５のいずれか１項に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 5 , wherein the inhibitor is sildenafil. １日あたりの投与量が５〜５００ｍｇである、請求項６記載の医薬組成物。 The pharmaceutical composition according to claim 6 , wherein the daily dose is 5 to 500 mg. １日あたりの投与量が１０〜１００ｍｇである、請求項７記載の医薬組成物。 The pharmaceutical composition according to claim 7 , wherein the daily dose is 10 to 100 mg. ｃＧＭＰ ＰＤＥ５阻害剤を、ＰＣＰ及び／又はＰＤＥ４阻害剤と組み合わせて含む、瘢痕化を減少させるため及び／又は繊維症を治療するための医薬組成物。A pharmaceutical composition for reducing scarring and / or treating fibrosis comprising a cGMP PDE5 inhibitor in combination with a PCP and / or PDE4 inhibitor. ＰＤＥ５阻害剤を含む医薬組成物、瘢痕化を減少させるため及び／又は繊維症を治療するための当該組成物の使用に関する指示書、及び容器を含む医薬パック。 A pharmaceutical composition comprising a PDE5 inhibitor, instructions for use of the composition to reduce scarring and / or to treat fibrosis, and a pharmaceutical pack comprising a container. ＰＤＥ５阻害剤と、ＰＣＰ阻害剤及び／又はＰＤＥ４阻害剤（ｕＰＡ）との組合せ剤。 A combination of a PDE5 inhibitor and a PCP inhibitor and / or a PDE4 inhibitor (uPA).
JP2003563565A 2002-01-31 2003-01-21 Use of PDE5 inhibitors in the treatment of scarring and fibrosis Pending JP2005523263A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring
PCT/IB2003/000134 WO2003063875A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis

Publications (2)

Publication Number Publication Date
JP2005523263A JP2005523263A (en) 2005-08-04
JP2005523263A5 true JP2005523263A5 (en) 2005-12-22

Family

ID=9930135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563565A Pending JP2005523263A (en) 2002-01-31 2003-01-21 Use of PDE5 inhibitors in the treatment of scarring and fibrosis

Country Status (8)

Country Link
EP (1) EP1469857A1 (en)
JP (1) JP2005523263A (en)
BR (1) BR0307410A (en)
CA (1) CA2474852A1 (en)
GB (1) GB0202254D0 (en)
MX (1) MXPA04007430A (en)
TW (1) TW200302105A (en)
WO (1) WO2003063875A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544040A (en) * 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
US8299083B2 (en) 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
DK1759700T3 (en) * 2004-08-19 2009-10-12 Switch Biotech Llc Use of a PDE5 inhibitor for the treatment and prevention of hypopigmentation disorders
AU2005274546B2 (en) 2004-08-19 2011-02-03 Switch Biotech, Llc Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
EP1838319B1 (en) 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
DE102005001989A1 (en) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenous formulations of PDE inhibitors
WO2006111198A1 (en) * 2005-04-18 2006-10-26 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease
EP1888074B1 (en) * 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
AR079451A1 (en) 2009-12-18 2012-01-25 Nycomed Gmbh COMPOUNDS 3,4,4A, 10B-TETRAHIDRO-1H-TIOPIRANO [4,3-C] ISOQUINOLINA
JP2013523809A (en) * 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Composition for improving skin wrinkle containing PDE5 inhibitor
CA2955143C (en) * 2010-05-26 2020-02-11 Claudia Hirth-Dietrich The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
CN103826638B (en) * 2011-09-09 2015-11-25 Sk化学公司 The compositions of the minimizing wrinkle of skin containing PDE5 inhibitor
AT512084A1 (en) 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
EP2992885A3 (en) * 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
EP3595623B1 (en) 2017-03-14 2024-05-01 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
US11033549B2 (en) 2017-03-14 2021-06-15 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
CN112773898A (en) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 Application of phosphodiesterase 5 inhibitor in preparing anti-fibrosis disease medicine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
AU5067098A (en) * 1997-11-26 1999-06-15 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives with cgmp-pde inhibitory activity
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Similar Documents

Publication Publication Date Title
JP2005523263A5 (en)
JP2009518415A5 (en)
RU2335493C2 (en) Quinoline derivatives as phosphodiesterase inhibitors
NO20061254L (en) Pharmaceutical mixtures
WO2003099223A3 (en) Copper lowering treatment of inflammatory and fibrotic diseases
UY28958A1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA
AU2001282988B2 (en) Methods for treating atopic disorders
JP2023166406A5 (en)
JP2005515964A5 (en)
HU228927B1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis, or conjunctivitis
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
JP2006182786A5 (en)
RU2007107915A (en) MEDICINES FOR TREATMENT OF CHRONIC RESPIRATORY DISEASES
JP2006518387A5 (en)
JP2015057436A5 (en)
CO5550426A2 (en) NOVEDOUS THERAPEUTIC METHOD
JP2023088944A5 (en)
JP2006512324A5 (en)
PE20070828A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A GLYCOPYRONIUM SALT
JP2023076632A5 (en)
WO2005011614A8 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
JP2008542290A (en) Methods and compositions for using 4-[(cyclopropanecarbonylamino) methyl] -2- (2,6-dioxopiperidin-3-yl) isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
JP2005513014A5 (en)
JP2002534477A5 (en)
JP2005537282A5 (en)